FDA Signs Cooperative Agreement To Develop Standards For Warfarin-Dosing Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
The Critical Path Institute, in conjunction with the University of Utah, will be awarded $750,000 in funding by FDA to be used, in part, to validate and standardize genetic testing for biomarkers related to warfarin efficacy and metabolism.
You may also be interested in...
Cost Effectiveness Of Warfarin Dose Genotyping To Be Assessed In Medco/Mayo Clinic Study
Study will determine if the cost of testing is justified by the savings created in preventing warfarin-related bleeding events.
Cost Effectiveness Of Warfarin Dose Genotyping To Be Assessed In Medco/Mayo Clinic Study
Study will determine if the cost of testing is justified by the savings created in preventing warfarin-related bleeding events.
HHS Should Encourage Prospective Outcome Studies of Pharmacogenetic Drug Dosing, SACGHS Says
One example of the value of genotyping is Genentech's Herceptin, committee members agreed.